Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults

NCT03455140 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT03455140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03455140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults
Lead sponsor
University of Birmingham
Phase
Phase 1/2
Overall status
Completed
Start date
August 28, 2018
Completion date
July 22, 2022
Enrollment
49 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, pediatric all, pediatric aml, pediatric solid tumor